These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34725056)

  • 21. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies.
    Pijls BG; Jolani S; Atherley A; Derckx RT; Dijkstra JIR; Franssen GHL; Hendriks S; Richters A; Venemans-Jellema A; Zalpuri S; Zeegers MP
    BMJ Open; 2021 Jan; 11(1):e044640. PubMed ID: 33431495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD.
    Bamias G; Kokkotis G; Christidou A; Christodoulou DK; Delis V; Diamantopoulou G; Fessatou S; Gatopoulou A; Giouleme O; Kafritsa P; Kalantzis C; Kapsoritakis A; Karatzas P; Karmiris K; Katsanos K; Kevrekidou P; Kosmidis C; Mantaka A; Mathou N; Michalopoulos G; Michopoulos S; Papaconstantinou I; Papatheodoridis G; Polymeros D; Potamianos S; Poulopoulos G; Protopapas A; Sklavaina M; Soufleris K; Theocharis G; Theodoropoulou A; Triantafillidis JK; Triantafyllou K; Tsiolakidou G; Tsironi E; Tzouvala M; Viazis N; Xourgias V; Zacharopoulou E; Zampeli E; Mantzaris GJ
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e810-e817. PubMed ID: 34402469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data.
    Macaluso FS; Orlando A
    Dig Liver Dis; 2020 Nov; 52(11):1222-1227. PubMed ID: 32928672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
    El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
    Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic.
    Kamath C; Brenner EJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100101. PubMed ID: 35496814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
    Viganò C; Mulinacci G; Palermo A; Barisani D; Pirola L; Fichera M; Invernizzi P; Massironi S
    World J Gastroenterol; 2021 Sep; 27(33):5520-5535. PubMed ID: 34588749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients.
    Waggershauser CH; Tillack-Schreiber C; Weyh P; Alt E; Siegmund T; Berchthold-Benchieb C; Szokodi D; Schnitzler F; Ochsenkühn T
    Can J Gastroenterol Hepatol; 2022; 2022():3469789. PubMed ID: 36060521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
    Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
    [No Abstract]   [Full Text] [Related]  

  • 30. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.
    Rozich JJ; Dulai PS; Fumery M; Sandborn WJ; Singh S
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2437-2447.e6. PubMed ID: 32142940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
    Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
    Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation.
    Sleutjes JAM; Roeters van Lennep JE; van der Woude CJ; de Vries AC
    Inflamm Bowel Dis; 2023 Apr; 29(4):531-538. PubMed ID: 35590447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indications and safety of newer IBD treatments in the older patient.
    Clement B; De Felice K; Afzali A
    Curr Gastroenterol Rep; 2023 Jul; 25(7):160-168. PubMed ID: 37227615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
    Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Ungaro RC; Brenner EJ; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gut; 2021 Apr; 70(4):725-732. PubMed ID: 33082265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients.
    Azzam NA; Aljebreen A; Almuhareb A; Almadi MA
    Saudi J Gastroenterol; 2020; 26(5):256-262. PubMed ID: 32415045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study.
    Peng YL; Chang CH; Wei SC; Huang TY; Tai WC; Hsu WH; Wu DC; Yen HH; Tai CM; Chang CW; Lin WC; Wang HY; Lin CC; Kuo CJ; Chiu CT; Lin CP; Lee HC; Wu JF; Chung CS
    J Formos Med Assoc; 2023 Oct; 122(10):1042-1049. PubMed ID: 37019722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study.
    Gilissen LPL; Heinen SGH; Rijpma-Jacobs L; Schoon E; Schreuder RM; Wensing AM; van der Ende-van Loon MCM; Bloemen JG; Stapelbroek JM; Stronkhorst A
    Clin Exp Med; 2022 Aug; 22(3):465-476. PubMed ID: 34542781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study.
    Lund LC; Kristensen KB; Reilev M; Christensen S; Thomsen RW; Christiansen CF; Støvring H; Johansen NB; Brun NC; Hallas J; Pottegård A
    PLoS Med; 2020 Sep; 17(9):e1003308. PubMed ID: 32898149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.